INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $746 | -16.9% | 14,327 | +1.1% | 0.01% | -14.3% |
| Q2 2023 | $898 | +27.7% | 14,175 | +9.1% | 0.01% | +16.7% |
| Q1 2023 | $703 | -11.7% | 12,988 | -13.6% | 0.01% | -14.3% |
| Q4 2022 | $796 | -99.9% | 15,036 | +1.4% | 0.01% | 0.0% |
| Q3 2022 | $690,000 | -17.6% | 14,823 | +1.1% | 0.01% | -12.5% |
| Q2 2022 | $837,000 | +3.8% | 14,662 | +11.3% | 0.01% | +33.3% |
| Q1 2022 | $806,000 | -38.1% | 13,172 | -47.0% | 0.01% | +20.0% |
| Q4 2021 | $1,302,000 | +177.6% | 24,876 | +97.9% | 0.01% | +25.0% |
| Q3 2021 | $469,000 | -13.9% | 12,573 | -5.8% | 0.00% | 0.0% |
| Q2 2021 | $545,000 | +132.9% | 13,346 | +93.3% | 0.00% | -55.6% |
| Q1 2021 | $234,000 | -1.7% | 6,905 | -7.9% | 0.01% | 0.0% |
| Q4 2020 | $238,000 | -13.5% | 7,496 | -6.4% | 0.01% | +80.0% |
| Q4 2019 | $275,000 | – | 8,009 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |